TY - JOUR
T1 - mRNA-based CAR T cell engineering
T2 - Unmodified mRNA enables high CAR expression without innate immune activation in T cells
AU - Kahwaji, Nourhan
AU - Kotzian, Niklas
AU - Prinz, Jasmin Melissa
AU - Pu, Yaolin
AU - Kath, Jonas
AU - Picht, Samira
AU - Hiller, Anna Luisa
AU - Klaas, Antonia
AU - Dunne, Charlotte Maeve
AU - Launspach, Michael
AU - Palmowski, Andriko
AU - Kleyer, Arnd
AU - Simon, David Nils
AU - Wagner, Dimitrios Laurin
AU - Pichon, Chantal
AU - Krönke, Gerhard
AU - Schmueck-Henneresse, Michael
AU - Volk, Hans Dieter
AU - Gossen, Manfred
AU - Drzeniek, Norman Michael
N1 - Publisher Copyright:
© 2025 The Author(s).
PY - 2026/3/12
Y1 - 2026/3/12
N2 - Unmodified, uridine-containing mRNA is known to trigger antiviral immune responses, inflammatory signaling, and apoptosis in transfected cells. To avoid this and enable high expression, modified nucleosides such as N1-methylpseudouridine have become the gold standard for mRNA applications including T cell engineering, albeit at increased cost. Here, immune responses toward mRNA were evaluated across five primary human cell types. Remarkably, T cells, unlike other immune and non-immune cell types tested, exhibited no immune activation by unmodified mRNA. T cell viability and cytokine secretion remained unaffected, regardless of mRNA delivery method via lipid nanoparticles or electroporation. The absence of nucleotide modifications improved expression of chimeric antigen receptor (CAR) in activated T cells and CAR-T cell cytotoxic potency. By eliminating the need for mRNA-nucleoside modification in CAR-T cell engineering, our findings challenge existing paradigms and position mRNA as a non-inflammatory, minimally invasive and highly efficient tool for T cell engineering, while simplifying and reducing manufacturing cost.
AB - Unmodified, uridine-containing mRNA is known to trigger antiviral immune responses, inflammatory signaling, and apoptosis in transfected cells. To avoid this and enable high expression, modified nucleosides such as N1-methylpseudouridine have become the gold standard for mRNA applications including T cell engineering, albeit at increased cost. Here, immune responses toward mRNA were evaluated across five primary human cell types. Remarkably, T cells, unlike other immune and non-immune cell types tested, exhibited no immune activation by unmodified mRNA. T cell viability and cytokine secretion remained unaffected, regardless of mRNA delivery method via lipid nanoparticles or electroporation. The absence of nucleotide modifications improved expression of chimeric antigen receptor (CAR) in activated T cells and CAR-T cell cytotoxic potency. By eliminating the need for mRNA-nucleoside modification in CAR-T cell engineering, our findings challenge existing paradigms and position mRNA as a non-inflammatory, minimally invasive and highly efficient tool for T cell engineering, while simplifying and reducing manufacturing cost.
KW - CAR t cells
KW - chimeric antigen receptor
KW - DNA-free CAR T manufacturing
KW - immunogenicity
KW - innate immune activation
KW - lipid nanoparticles
KW - messenger RNA
KW - MT: Oligonucleotides: Therapies and Applications
KW - N1-methylpseudouridine
KW - nonviral gene transfer
KW - nucleoside modifications
KW - T cell engineering
KW - toll-like receptor
KW - unmodified mRNA
KW - uridine
UR - https://www.scopus.com/pages/publications/105030856227
U2 - 10.1016/j.omtn.2025.102805
DO - 10.1016/j.omtn.2025.102805
M3 - Journal article
C2 - 41834823
AN - SCOPUS:105030856227
SN - 2162-2531
VL - 37
JO - Molecular Therapy Nucleic Acids
JF - Molecular Therapy Nucleic Acids
IS - 1
M1 - 102805
ER -